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abstract
PURPOSE Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets amino-
peptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial
evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple myeloma (RRMM), a
population with an important unmet medical need.
PATIENTS AND METHODS Patients with RRMM refractory to pomalidomide and/or an anti-CD38 monoclonal
antibody received melflufen 40 mg intravenously on day 1 of each 28-day cycle plus once weekly oral
dexamethasone at a dose of 40 mg (20 mg in patients older than 75 years). The primary end point was overall
response rate (partial response or better) assessed by the investigator and confirmed by independent review.
Secondary end points included duration of response, progression-free survival, overall survival, and safety. The
primary analysis is complete with long-term follow-up ongoing.
RESULTS Of 157 patients (median age 65 years; median five prior lines of therapy) enrolled and treated, 119
patients (76%) had triple-class–refractory disease, 55 (35%) had extramedullary disease, and 92 (59%) were
refractory to previous alkylator therapy. The overall response rate was 29% in the all-treated population, with
26% in the triple-class–refractory population. In the all-treated population, median duration of response was
5.5months, median progression-free survival was 4.2 months, andmedian overall survival was 11.6months at a
median follow-up of 14 months. Grade $ 3 treatment-emergent adverse events occurred in 96% of patients,
most commonly neutropenia (79%), thrombocytopenia (76%), and anemia (43%). Pneumonia (10%) was the
most common grade 3/4 nonhematologic event. Thrombocytopenia and bleeding (both grade 3/4 but fully
reversible) occurred concomitantly in four patients. GI events, reported in 97 patients (62%), were predom-
inantly grade 1/2 (93%); none were grade 4.
CONCLUSIONMelflufen plus dexamethasone showed clinically meaningful efficacy and amanageable safety profile
in patients with heavily pretreated RRMM, including those with triple-class–refractory and extramedullary disease.
J Clin Oncol 39:757-767. © 2020 by American Society of Clinical Oncology
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INTRODUCTION
Despite the introduction of novel therapies and regi-
mens that have improved outcomes in multiple my-
eloma (MM),1,2 almost all patients will relapse.1,3 After
relapse, treatment choice is usually determined by the
class of and response to previous treatment and pa-
tient characteristics.2,3 Although class switching is
generally prioritized, this is becoming increasingly
difficult, not least because novel agents are commonly
administered in combination in earlier treatment lines,
resulting in disease resistant to multiple drug classes
as early as second-line therapy.2,3
Outcomes are particularly poor for patients with high-
risk cytogenetics, extramedullary disease, and MM
resistant to multiple drug classes, including those
with triple-class–refractory disease who represent
groups with a high unmet need.1,3,4 Furthermore,
patients with relapsed and refractory multiple mye-
loma (RRMM) may have comorbidities because of
age, disease symptoms, and cumulative toxicities
stemming from previous therapies.5,6 There is an
urgent requirement for agents with novel mechanisms
of action that are effective, safe, and tolerable and that
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Melphalan flufenamide (melflufen) is a first-in-class peptide-
drug conjugate that targets aminopeptidases and rapidly
and selectively releases alkylating agents into tumor cells.7-12
Melflufen is rapidly and passively taken up by cells because
of its high lipophilicity, thereby circumventing the develop-
ment of transporter-associated resistance.8,11,13 Intracellular
aminopeptidases hydrolyze melflufen to release hydro-
philic alkylating moieties.11 Melflufen and its metabolites
melphalan and desethyl-melflufen have equipotent
alkylating potential.11 Unlike previous aminopeptidase-
targeting therapies that directly inhibit aminopeptidase
activity, melflufen takes a novel approach by leveraging
increased aminopeptidase activity to selectively direct
potent cytotoxic agents into tumor cells.11,14,15 Melflufen
and its metabolites trigger robust and irreversible DNA
damage, have antiangiogenic effects, induce apoptosis—
resulting in potent antitumor activity in myeloma cells,
including those with resistance to melphalan, bortezomib,
and dexamethasone—and, importantly, retain activity in
myeloma cells with absent or impaired p53 function.8-10,16
Melflufen may also have activity in other hematologic ma-
lignancies (including immunoglobulin light chain amyloidosis
and leukemia) and solid tumors (including breast cancer and
ovarian cancer).11
The phase I/II, multicenter O-12-M1 trial established the
dosage of melflufen plus dexamethasone in patients who
had RRMM, received a median of four previous lines of
therapy (including lenalidomide and bortezomib), and had
disease refractory to their last line of therapy.17 In 45 pa-
tients treated with infusional melflufen 40 mg administered
on day 1 of each 28-day cycle and once weekly dexa-
methasone dosed at 40 mg, the overall response rate
(ORR) was 31%, the median duration of response (DOR)
was 8.4 months, the median progression-free survival
(PFS) was 5.7 months, and the median overall survival (OS)
was encouraging at 20.7 months. The safety profile of
melflufen was characterized primarily by hematologic
toxicities that were clinically manageable with appropriate
dose delays, dose reductions, and supportive care. Based
on these results, the efficacy and safety of melflufen plus
dexamethasone were therefore evaluated in the current
study in a larger population with heavily pretreated, re-
sistant, and poor-risk RRMM, including those with triple-
class–refractory disease, for whom few effective treatment
options exist.3
PATIENTS AND METHODS
Study Design and Participants
HORIZON (OP-106;ClinicalTrials.gov identifier:NCT02963493)
was apivotal, single-arm,multicenter, phase II study ofmelflufen
plus dexamethasone in patients with RRMM refractory to
pomalidomide and/or an anti-CD38 monoclonal antibody. Pa-
tients were enrolled from December 28, 2016, to October 14,
2019, at 17 sites (see theData Supplement, online only). Eligible
adult patients had an Eastern Cooperative Oncology Group
performance status score of 0-2, a previous diagnosis of MM
with disease progression, and measurable disease (serum
monoclonal protein $ 5 g/L, urine monoclonal protein
$ 200 mg per 24 hours, or serum immunoglobulin-free light
chain $ 100 mg/L, and abnormal serum immunoglobulin
kappa to lambda–free light chain ratio) at study entry. Patients
had received at least two prior lines of therapy, including an
immunomodulatory agent and proteasome inhibitor, and were
refractory to pomalidomide and/or an anti-CD38 monoclonal
antibody. RRMM was defined as disease that was nonre-
sponsive (ie, did not achieve a minimal response or better, or
developed progressive disease with treatment) while on primary
or salvage therapy or progressedwithin 60 days of last therapy.18
Please see theDataSupplement for full eligibility criteria. Patients
received once-monthly melflufen 40 mg as a 30-minute central
intravenous infusion on day 1 of each 28-day cycle in combi-
nation with oral dexamethasone 40 mg (20 mg for patients
CONTEXT
Key Objective
To evaluate whether melphalan flufenamide (melflufen) plus dexamethasone is effective and safe in patients with heavily
pretreated relapsed and refractory multiple myeloma (RRMM), a population with a high unmet medical need.
Knowledge Generated
In this pivotal, phase II study, melflufen plus dexamethasone showed meaningful efficacy in heavily pretreated patients with
RRMM, including patients with triple-class–refractory disease and those with extramedullary disease. The safety profile of
melflufen plus dexamethasone was consistent with previously reported data and was characterized primarily by clinically
manageable hematologic toxicities.
Relevance
As new combinations of antimyeloma drugs are introduced in earlier lines of therapy, patients with RRMM often have
disease that is refractory to multiple drugs. Therefore, drugs with novel mechanisms of action are urgently needed.
Melflufen, when combined with dexamethasone, has the potential to fill this unmet medical need by providing a novel
mechanism of action, clinically meaningful efficacy, and manageable safety in patients with RRMM.
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age $ 75 years) once-weekly administered on days 1, 8,
15, and 22 of each 28-day cycle until disease progression,
unacceptable toxicity, or the patient or treating physician
determined it was not in the patient’s best interest to
continue. Melflufen dose reduction for drug-related tox-
icities was allowed in 10 mg increments each cycle from
40 mg down to 30 mg and from 30 mg down to 20 mg (see
the Data Supplement).
This study was conducted in accordance with the Decla-
ration of Helsinki and International Conference on Har-
monisation guidelines for Good Clinical Practice. The
Protocol was reviewed and approved by national regulatory
authorities and an independent ethics committee or in-
stitutional review board at each study center. Each patient
provided written informed consent.
Outcomes
The primary end point was ORR, defined as the pro-
portion of patients achieving a confirmed response of
stringent complete response (sCR), complete response
(CR), very good partial response (VGPR), or partial re-
sponse (PR) as their best response per International
Myeloma Working Group (IMWG) uniform response
criteria, as assessed by the investigator.18 Response,
confirmed response, and confirmed progression were
subsequently verified by an independent review com-
mittee.18 Secondary end points included DOR, PFS, OS,
clinical benefit rate (CBR), best response, time to re-
sponse, time to progression, time to next treatment, and
safety (defined in the Data Supplement). All response
categories required confirmation with two consecu-
tive assessments (see the Data Supplement). Adverse
events (AEs) were graded according to the Common
Terminology Criteria for Adverse Events, version 4.03. AE
frequency and relationship to study treatment were
summarized.
Statistical Analysis
Planned enrollment was 150 patients. ORR and associated
two-sided exact 95% CI19 were estimated for all patients
treated (all-treated population). With a sample size of 150
patients and an assumed ORR of 30%, the exact 95% CI
was estimated to range between 23% and 38%. CBR and
disease stabilization were also summarized. Time-to-event
end points were summarized using the Kaplan-Meier
method in the all-treated population. Median and esti-
mated 95% CIs were constructed using the methods of
Brookmeyer and Crowley20; duration of follow-up was es-
timated by the reverse Kaplan-Meier methods of Schemper
and Smith.21 See the Data Supplement for patient cen-
soring and handling of missing data.
A preplanned subgroup analysis was performed in pa-
tients with triple-class–refractory MM (refractory to or
intolerant of at least one immunomodulatory drug, at least
one proteasome inhibitor, and at least one anti-CD38
monoclonal antibody). With a sample size of 150 pa-
tients, 104-120 patients with triple-class–refractory dis-
ease were expected; the primary end point was
considered met if the lower bound of the 95% CI for the
ORR was higher than 15%. Additional subgroup analyses,
including extramedullary disease, are described in the
Data Supplement. Extramedullary disease was assessed
at baseline for patients with known or suspected extra-
medullary disease and to confirm a response achieved by
M-protein or for suspected progression per IMWG uniform
response criteria.18
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FIG 1. Trial profile. OS, overall survival; PFS, progression-free survival.
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RESULTS
Patients
In total, 157 patients were enrolled in the study, received
at least one dose of study medication, and were included
in the all-treated population. At the data cutoff date
(January 14, 2020), 131 patients (83%) had discontinued
treatment—the most common primary reasons for dis-
continuation were disease progression (n5 88; 56%) and
AEs (n 5 26; 17%)—and 26 patients (17%) remained on
treatment (Fig 1). The median duration of treatment with
melflufen plus dexamethasone was 3.8 months (range,
0.9-22.7 months). At baseline, the median age was 65
years, patients had received a median of five prior lines
of therapy, 154 patients (98%) had disease that was









Median age (range), years 65 (35-86) 65 (35-86)
Male 89 (57) 70 (59)
ECOG performance status
scoreb
0 39 (25) 26 (22)
1 93 (59) 75 (63)
2 25 (16) 18 (15)
High-risk cytogeneticsc,d 59 (38) 41 (34)
$ 2 High-risk abnormalities 21 (13) 14 (12)
Del(17p) 18 (11) 10 (8)
International Staging System
staged,e
I 63 (40) 41 (34)
II 49 (31) 36 (30)
III 39 (25) 36 (30)
Unknown 4 (3) 4 (3)
Missing 2 (1) 2 (2)
Extramedullary diseased,f 55 (35) 50 (42)
Median time since initial
diagnosis (range), yearsg
6.5 (0.7-24.6) 6.2 (0.7-24.6)
Median no. of prior lines of
therapy (range)
5 (2-12) 5 (2-12)
Previous anti-CD38
monoclonal antibody
125 (80) 119 (100)
Refractory (any) 125 (80) 119 (100)
Refractory to daratumumab 117 (75) 112 (94)
Previous immunomodulatory
drug
157 (100) 119 (100)
Refractory (any) 153 (97) 116 (97)
Refractory to pomalidomide 140 (89) 104 (87)
Previous proteasome inhibitor 157 (100) 119 (100)
Refractory (any) 145 (92) 115 (97)
Refractory to bortezomib 101 (64) 80 (67)
Previous alkylator therapy 138 (88) 105 (88)
Refractory (any) 92 (59) 76 (64)
Refractory to
cyclophosphamide
80 (51) 65 (55)
Refractory to melphalan 21 (13) 19 (16)
Refractory to bendamustine 14 (9) 13 (11)
Refractory to otherh 10 (6) 7 (8)
Triple-class refractoryi 119 (76) 119 (100)
(continued in next column)









Refractory to the last line of
therapy
154 (98) 117 (98)
Previous stem-cell transplant
$ 1 108 (69) 81 (68)
$ 2 33 (21) 24 (20)
NOTE. Data are expressed as no. (%) unless otherwise indicated.
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
aBaseline is defined as the most recent assessment before
administration of the first dose of study drug.
bECOG performance status scores range from 0 to 5, with 0
indicating no symptoms and higher scores indicating increasing
disability, and were established at baseline (most recent assessment
before administration of the first dose of study drug).
cHigh-risk cytogenetics at study entry was based on fluorescence in
situ hybridization defined as t(4; 14), del(17/17p), and t(14; 16) per
Sonneveld et al22; 31 patients (20%) had unknown cytogenetics.
Cytogenetic assessments were not centralized.
dAt study entry.
eInternational Staging System stages were defined as follows: stages I,
serum B2-microglobulin, 3.5 mg/L, serum albumin $ 3.5 g/dL; stage
II, not stage I or stage III; stage III, serum B2-microglobulin$ 5.5 mg/L.
Patients with unknown status were coded as unknown; patients without
an entry into the case report form were coded as missing.
fExtramedullary disease was defined as a multiple myeloma disease
originating either in, but extending beyond, the cortical bone or as a
separate soft tissue mass.
gTime since initial diagnosis is calculated relative to the first dose of
study drug.
hIncludes patients refractory to carmustine (6 [7%] in the all-treated
population; 6 [5%] in the triple-class–refractory population), refractory
to high-dose melphalan (3 [3%] in the all-treated population; 2 [2%] in
the triple-class–refractory population), and refractory to busulfan (1
[1%] each in the all-treated and triple-class–refractory population).
iDefined as refractory to or intolerant of $ 1 proteasome inhibitor,
$ 1 immunomodulatory drug, and $ 1 anti-CD38 monoclonal
antibody.
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refractory to the last line of therapy received, 119 (76%)
had triple-class–refractory disease, and 92 (59%) had
MM that was refractory to prior alkylator therapy (Table 1).
Overall, 59 patients (38%) had high-risk cytogenetics, 39
(25%) had International Staging System stage III disease,
and 55 (35%) had extramedullary disease.
Efficacy
The ORR per investigator assessment was 29% (95% CI,
22% to 37%), with one patient achieving an sCR, 17 a
VGPR, and 28 a PR (Table 2). An additional 25 patients
achieved a minimal response for a CBR of 45% (95% CI,
37% to 53%). In the triple-class–refractory population,
the ORR was 26% (95% CI, 18% to 35%), with 13 pa-
tients achieving a VGPR and 18 a PR. The ORR per
independent review committee was 30% (95% CI, 23% to
38%) overall and 26% (95% CI, 18% to 35%) in the
triple-class–refractory population (Data Supplement).
Reduction in M-protein was observed in 118 of the 145
patients (81.4%) (Data Supplement). In the all-treated
and triple-class–refractory populations, the median time
to PR or better was 1.9 months (range, 1.0-7.4 months)
and 1.9 months (range, 1.0-6.1 months), respectively,
and the median duration of PR or better was 5.5 months
TABLE 2. Overall Response and Clinical Benefit Rate
Response Category All-Treated Population (N 5 157) Triple-Class Refractory (n 5 119)
Best overall responsea
sCR 1 (1) 0
CR 0 0
VGPR 17 (11) 13 (11)
PR 28 (18) 18 (15)
Minimal response 25 (16) 16 (13)
ORRb 46 (29) [22 to 37] 31 (26) [18 to 35]
CBRc 71 (45) [37 to 53] 47 (39) [31 to 49]
NOTE. Data are expressed as no. (%) [95% CI].
Abbreviations: CBR, clinical benefit rate; CR, complete response; ORR, overall response rate; PR, partial response; sCR, stringent complete response;
VGPR, very good partial response.
aInvestigator assessed per the International Myeloma Working Group uniform response criteria.18
bDefined as the proportion of patients with a PR or better.
cDefined as the proportion of patients with a minimal response or better.
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Patients with triple-class−refractory disease (n = 31)
Patients with extramedullary disease (n = 13)
Progression-free survival event
FIG 2. Duration of response to melflufen plus dexamethasone. Data on patients in the all-treated population (n5 46),
triple-class–refractory population (asterisk; n5 31), and extramedullary subgroup (dagger; n5 13) who achieved aPR
or better as the best response. Open circles indicate the latest dose of melflufen received; arrows indicate patients still
receiving treatment at the data cutoff date; orange Xs indicate progression-free survival events. CR, complete response;
MR, minimal response; PR, partial response; sCR, stringent complete response; SD, stable disease; VGPR, very good
partial response.
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(95% CI, 3.9 to 7.6 months) and 4.4 months (95% CI, 3.4 to
7.6 months), respectively (Fig 2 and Data Supplement).
In the all-treated and triple-class–refractory populations, the
median PFS was 4.2months (95%CI, 3.4 to 4.9months) and
3.9months (95%CI, 3.0 to 4.6months), respectively (Fig 3A).
The median OS was 11.6 months (95% CI, 9.3 to
15.4months) and 11.2months (95%CI, 7.7 to 13.2months),
with an estimated 1-year event-free rate of 48.8% (95% CI,
39.6% to 57.4%) and 41.9% (95% CI, 31.6% to 51.8%),
respectively (Fig 3B), at a median follow-up of 14 months
(range, 10.8-18.7 months). Among responders, the median
PFS was 8.5 months (95% CI, 5.4 to 13.4 months) and
8.5months (95%CI, 5.3 to 13.4months), and themedian OS
was 17.6 months (95% CI, 13.2 to 28.9 months) and
16.5 months (95% CI, 11.5 to 18.5 months) in the all-treated
and triple-class–refractory populations, respectively (Data
Supplement). Among patients in the all-treated population
and the triple-class–refractory group (n 5 70 and n 5 52,
respectively) who discontinued the study and initiated a new
myeloma therapy, the median time to next therapy was
8.2 months (95% CI, 7.2 to 10.8 months) and 7.9 months
(95% CI, 6.9 to 10.9 months), respectively. The median time
to next therapy or death was 5.8 months (95% CI, 4.8 to
7.1 months) in the all-treated population and 5.3 months
(95% CI, 4.5 to 6.3 months) in the triple-class–refractory
group.
In a subgroup analysis, 19 of the 54 patients (35%) age 65-
74 years and 8 of the 25 patients (32%) older than 75 years
achieved a PR or better. In addition, a PR or better was
achieved in 13 of the 55 patients (24%) with extramedullary
157 (0) 0 (36)91 (9) 46 (13) 22 (23) 9 (31) 5 (33) 3 (34) 1 (35)
119 (0) 64 (9) 26 (13) 15 (17) 6 (21) 3 (23) 2 (24) 0 (25)
All-treated
Triple-class–refractory
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FIG 3. PFS and OS. Kaplan-Meier analysis of (A) PFS and (B) OS in the all-treated (N5 157) and triple-class–
refractory (n 5 119) populations. OS, overall survival; PFS, progression-free survival.
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disease and 12 of the 59 patients (20%) with high-risk
cytogenetics (Data Supplement). Among patients with MM
refractory to previous alkylator therapy, the ORR was 21%
(19 of the 92 patients achieved a PR or better, including
one sCR, six VGPRs, and 12 PRs) and the CBR was 34%
(Data Supplement). Among patients refractory to an alky-
lator in one previous line of therapy (n5 60), the ORR was
28% (CBR, 40%). In patients refractory to alkylators in
multiple previous lines of therapy (n 5 32), the ORR was
6% (CBR, 22%). Median PFS and OS in the subgroups
analyzed were consistent with those of the all-treated
population (Data Supplement).
Safety
Treatment-emergent AEs (TEAEs) were reported in all 157
patients (100%) in the all-treated population, with 149
(95%) reporting at least one melflufen-related TEAE
(Table 3 and Data Supplement). Grade $ 3 TEAEs oc-
curred in 150 patients (96%), most commonly neutropenia
(124 [79%]), thrombocytopenia (120 [76%]), and anemia
(67 [43%]). Any-grade and grade 3/4 bleeding events with
concurrent grade 3/4 thrombocytopenia occurred in 25
patients (16%) and four patients (3%), respectively. The
most common nonhematologic treatment-emergent grade
3/4 events included pneumonia (16 [10%]; grade 3, 14
[9%]; grade 4, two [1%]) and hypophosphatemia (eight
[5%]; grade 3, eight [5%]; grade 4, 0). Grade 3/4 neu-
tropenia with concurrent grade 3/4 infections occurred in
18 patients (11%); of these, 11 (7%) had pneumonia (Data
Supplement). GI events occurred in 97 patients overall and
were grade 1/2 in 90 of the 97 patients (93%) and grade 3
in seven of the 97 patients (7%). No grade 4 events were
reported. The most common any-grade GI events included
nausea (50 [32%]), diarrhea (42 [27%]), constipation (23
[15%]), and vomiting (21 [13%]). Mucositis occurred in
one patient (1%; grade 1 event), and there were no reports
of alopecia or neuropathy.
Serious TEAEs occurred in 77 patients (49%), most
commonly pneumonia (14 [9%]) and febrile neutropenia
(eight [5%]; Data Supplement). Second primary malig-
nancies occurred in five patients; of these, four had
malignancies with cutaneous manifestations (two patients
with basal cell carcinoma, one patient with squamous cell
carcinoma, and one patient with basal cell carcinoma,
squamous cell carcinoma, and malignant melanoma; see
the Data Supplement). One patient developed myelo-
dysplasia after having received 17 cycles of study medi-
cation and in the context of multiple prior cycles of
alkylator-based therapy, including stem-cell transplant
prior to study entry. Moreover, the review of fluorescence
in situ hybridization studies from the screening bone
marrow confirmed pre-existing abnormalities supporting a
subclinical myelodysplastic syndrome that was likely
treatment-related and not otherwise apparent. No other
cases of myelodysplastic syndromes were seen. Overall,
10 patients (6%) died from TEAEs. Most commonly,
general physical health deterioration was associated with
progressive disease (n 5 3; 2%) and respiratory failure
(n 5 2; 1%; Data Supplement). None of the deaths were
considered related to melflufen.
The average (standard deviation) monthly dose of melflufen
received was 37.8 mg (6 4.0). TEAEs leading to melflufen
dose reductions occurred in 42 patients (27%), most
commonly thrombocytopenia (n 5 22; 14%) and neu-
tropenia (n 5 5; 3%). While on study, 102 patients (65%)
received concomitant RBC or platelet transfusion support,
with 68 (43%) receiving platelet transfusion support only
and 106 (68%) receiving concomitant growth factor sup-
port (Data Supplement). Overall, 34 patients (22%) had at
least one TEAE leading to melflufen treatment discontin-
uation, most commonly thrombocytopenia (n 5 16) and
neutropenia (n5 5; Data Supplement). Overall, 95 patients
(61%) experienced at least one dose delay, and themedian
number of treatment cycles with a dose delay was one
(range, 0-9).
DISCUSSION
In this study, melflufen plus dexamethasone demon-
strated meaningful efficacy and a manageable safety
profile in patients with heavily pretreated RRMM. These
findings build substantially on previously reported re-
sults17 but in a population that is more aligned with current
treatment practice in the relapsed and refractory as well as
highly resistant disease setting (ie, patients refractory to an
anti-CD38 monoclonal antibody and/or pomalidomide,
as well as exposed and refractory to prior lenalidomide,
dexamethasone, and proteasome inhibitors). Durable
responses were seen in this heavily pretreated population
with a high proportion of extramedullary disease and high-
risk cytogenetic features. Although the median DOR was
5.5 months, the median PFS among responders was
encouragingly longer at 8.5 months. Furthermore, the
median time to first response was 1.9 months, but many
patients achieved their best response beyond 2 months of
treatment. Altogether, these data support the notion that
the clinical benefit of melflufen plus dexamethasone
improves with longer treatment duration.
The ORR of 29% was consistent among high-risk patient
subgroups, including those with triple-class–refractory
disease (26%), those with extramedullary disease (24%),
and patients age 75 years or older (32%), which is en-
couraging given the reported ORRs (10%-31%) in patients
refractory to anti-CD38 monoclonal antibody therapy and/
or with extramedullary disease at relapse.3,4,23-25 In fact, this
is the largest population with extramedullary disease re-
ported to date in a prospective study.4,26,27 Subgroup an-
alyses showed sufficient efficacy in 60 patients refractory to
an alkylator in one previous line of therapy with an ORR of
28%, while the ORR was only 6% in the 32 patients re-
fractory to alkylators in two or more previous lines. Melflufen
may have a mechanism of action that is different from that
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of other alkylators.8,11 For example, melflufen induced cell
death more effectively than melphalan in TP53-mutated
cell lines and in cells from patients with TP53-mutated
RRMM, suggesting that the mechanism of cytotoxicity of
melflufen—but not that of other alkylators—is independent
of p53 function.8,11,16 Unlike other newer agents that
work via immune-based mechanisms (including chimeric
antigen receptor T cell therapy, belantamab mafodotin,
iberdomide, and isatuximab), melflufen adds a unique
mechanism of action to the treatment landscape in
TABLE 3. TEAEs (Occurring in $ 10% of Patients) in the All-Treated Population
TEAEa
Patients (N 5 157)
Any-Gradeb Grade 1 Grade 2 Grade 3 Grade 4
Anyc,d 157 (100) 0 7 (4) 40 (25) 100 (64)
Hematologic
Neutropeniae 129 (82) 1 (, 1) 4 (3) 50 (32) 74 (47)
Thrombocytopeniae 128 (82) 5 (3) 3 (2) 40 (25) 80 (51)
Anemiae 111 (71) 3 (2) 41 (26) 66 (42) 1 (, 1)
Nonhematologic
Nausea 50 (32) 31 (20) 18 (11) 1 (, 1) 0
Fatigue 46 (29) 17 (11) 25 (16) 4 (3) 0
Asthenia 42 (27) 13 (8) 23 (15) 5 (3) 1 (, 1)
Diarrhea 42 (27) 24 (15) 18 (11) 0 0
Pyrexia 38 (24) 24 (15) 11 (7) 3 (2) 0
Cough 26 (17) 16 (10) 10 (6) 0 0
Upper respiratory tract infection 25 (16) 3 (2) 19 (12) 3 (2) 0
Constipation 23 (15) 18 (11) 4 (3) 1 (, 1) 0
Decreased appetite 22 (14) 10 (6) 11 (7) 1 (, 1) 0
Hypokalemia 22 (14) 14 (9) 6 (4) 2 (1) 0
Peripheral edema 22 (14) 15 (10) 5 (3) 2 (1) 0
Headache 21 (13) 13 (8) 8 (5) 0 0
Vomiting 21 (13) 12 (8) 9 (6) 0 0
Bone pain 20 (13) 9 (6) 8 (5) 3 (2) 0
Pain in extremity 20 (13) 7 (4) 10 (6) 3 (2) 0
Pneumonia 20 (13)f 0 3 (2) 14 (9) 2 (1)
Back pain 19 (12) 9 (6) 9 (6) 1 (, 1) 0
Insomnia 18 (11) 14 (9) 3 (2) 1 (, 1) 0
Dizziness 17 (11) 14 (9) 3 (2) 0 0
Dyspnea 17 (11) 9 (6) 6 (4) 2 (1) 0
Arthralgia 16 (10) 11 (7) 5 (3) 0 0
Exertional dyspnea 16 (10) 13 (8) 3 (2) 0 0
Hypocalcemia 16 (10) 9 (6) 6 (4) 1 (, 1) 0
NOTE. Data are expressed as no. (%).
Abbreviation: TEAE, treatment-emergent adverse event.
aAdverse events are coded to the preferred term using MedDRA, version 19.1.
bAt each level of summarization (any event and preferred term), patients reportingmore than one incidence of each adverse event are counted only once by
maximum severity.
cTEAEs were defined as adverse events with onset date/time or increase in the severity level after the initial dose of study drug and within 30 days (unless
considered related to study drug) after the last dose of study drug or initiation of new multiple myeloma therapy, whichever occurred sooner.
dIncludes 10 patients who experienced grade 5 TEAEs.
eHematologic TEAEs of special interest were categorized by standardized MedDRA query. For anemia, the preferred terms under hematopoietic
erythropenia were counted. For neutropenia, the preferred terms under hematopoietic leukopenia were combined. For thrombocytopenia, the preferred
terms under hematopoietic thrombocytopenia were combined.
fIncludes one grade 5 event.
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relapsed disease as a potent and novel cytotoxic agent
targeting myeloma more broadly while providing mean-
ingful clinical efficacy and a manageable safety profile for
heavily pretreated RRMM.8,10,28-30
The safety profile of melflufen primarily consisted of
hematologic AEs, consistent with previous results.17
Despite cytopenias being common, the incidence of
significant bleeding events or infections was low. He-
matologic AEs were generally reversible and clinically
manageable with dose adjustments, dose delays, growth
factor use, platelet transfusions, and appropriate sup-
portive care. Nonhematologic grade 3/4 AEs were in-
frequent, with infections being the most common.
Moreover, the frequency of infections was generally
consistent with the expected rates of infections in heavily
pretreated patients.23,27,31 Specifically, the 10% rate of
grade 3/4 pneumonia reported in HORIZON was similar
to 9%-11% reported with pomalidomide plus dexa-
methasone, bortezomib plus dexamethasone, and seli-
nexor plus dexamethasone in RRMM.23,27,31 GI toxicities,
a common reason for treatment discontinuation with
other agents,23 were infrequent, primarily grade 1/2,
and did not lead to melflufen treatment cessation in
HORIZON in any patient. Encouragingly, alopecia and
treatment-emergent peripheral neuropathy were not
reported. Patients were therefore able to tolerate treat-
ment, with rates of discontinuation from AEs lower than
or comparable with other studies (which range from 6%
to 33%) in this patient population and with a prolonged
median duration of treatment, together with the added
convenience of monthly infusions, which is an especially
important consideration in the current era of COVID-
19.23,27,28
In conclusion, the results from HORIZON suggest that
melflufen has the potential to be an important therapeutic
option in RRMM by providing a novel mechanism of action,
clinically meaningful efficacy, and manageable safety when
combined with dexamethasone in heavily pretreated pa-
tients.32 Based on these results, the efficacy and safety of
melflufen plus dexamethasone versus pomalidomide plus
dexamethasone are being further evaluated in OCEAN
(OP-103), a randomized, global, phase III multicenter study
(ClinicalTrials.gov identifier: NCT03151811) for patients in
earlier relapse.33 Studies of melflufen plus dexamethasone in
combination with bortezomib or daratumumab are also
ongoing, with promising results to date.34
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10Centre de Recherche en Cancérologie et Immunologie Nantes-Angers
(CRCINA), Institut National de la Santé et de la Recherche Médicale
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APPENDIX
TABLE A1. HORIZON (OP-106) Investigators and Recruitment Sites
Principal Investigator Recruitment Site
Paul Richardson Dana-Farber Cancer Institute
Adrián Alegre Hospital Universitario La Princesa
Joan Bladé Hospital Clı́nic de Barcelona
Michele Cavo Ematologia “L. e A. Seragnoli”—PAD 8. Policlinico Sant’Orsola-Malpighi
Hani Hassoun Memorial Sloan Kettering Cancer Center
John Hiemenza University of Florida Health Cancer Center
Maxim Norkin
Jan Moreb
Ramomohana Kancherlaa Hudson Valley Hematology and Oncology Associates
Amitabha Mazumder
Alessandra Larocca Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di
Torino
Xavier Leleu CHU de Poitiers-Pole regional de cancerologie
Christopher Maisel Baylor Scott & White Charles A. Sammons Cancer Center
Marı́a-Victoria Mateos Hospital Clı́nico Universitario de Salamanca/IBSAL/CIC
Amitabha Mazumder The Oncology Institute of Hope and Innovation
Albert Oriol Hospital Germans Trias i Pujol
Agne Paner RUSH University Medical Center
Anastasios Raptis University of Pittsburgh School of Medicine Hillman Cancer Institute
Paula Rodrı́guez-Otero Clinica Universidad de Navarra
Cyrille Touzeau Service d’hématologie Clinique, Centre Hospitalier Universitaire
aFor institutions at which a principal investigator change occurred throughout the course of the study, the current principal investigator is listed in bold.
Journal of Clinical Oncology
Melflufen and Dexamethasone in Relapsed and Refractory Myeloma
Downloaded from ascopubs.org by 62.83.88.102 on June 15, 2021 from 062.083.088.102
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 
